Voyager Therapeutics Inc Overview
Industry: Biotechnology
Sector: Healthcare
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; supe Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Voyager Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $3.2M (-38% YoY). Net loss was -$24.5M (from $33.4M). R&D expense was $22M.
Revenue
$3.2M
-38% YoY
Net loss
-$24.5M
from $33.4M
R&D expense
$22M
reported
G&A expense
$7.5M
reported
What changed
- Revenue -38% YoY to $3.2M.
- Net loss was -$24.5M (from $33.4M).
Guidance / outlook
the company expects its cash, cash equivalents, and marketable securities, together with anticipated collaboration reimbursements and interest income, to be sufficient to fund planned operating expenses and capital expenditures into 2028. About Voyager Therapeutics Voyager Therapeutics, Inc.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates
Headline from Investing.com: Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates.
Voyager Therapeutics: Q2 Earnings Snapshot
Headline from Yahoo Finance: Voyager Therapeutics: Q2 Earnings Snapshot.
VYGR Oct 2026 9.000 call (VYGR261016C00009000) stock price, news, quote and history
Headline from Yahoo Finance Australia: VYGR Oct 2026 9.000 call (VYGR261016C00009000) stock price, news, quote and history.
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Headline from Yahoo Finance: Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates.
Voyager Reports Second Quarter 2026 Financial and Operating Results
Headline from GlobeNewswire: Voyager Reports Second Quarter 2026 Financial and Operating Results.
VYGR 8-K & SEC Filings
Headline from Yahoo Finance: VYGR 8-K & SEC Filings.
Earnings Per Share
Score 3.00/5
Voyager Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.44/5
Voyager Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 1.74/5
Voyager Therapeutics Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.11/5
Voyager Therapeutics Inc
registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
have achieved high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios